Codification of a November 2023 classification
The U.S. Food and Drug Administration published a final amendment and final order on 9 October 2026, adding 21 CFR 870.2705 for infant pulse rate and oxygen saturation monitors for over-the-counter use. The order is effective on that date, while the classification was applicable on 8 November 2023, when FDA granted the Dream Sock De Novo request.
The seven groups of special controls were already set out in the 2023 classification letter. The 2026 action should therefore be described as codification, rather than the first authorisation of this device type or the creation of an entirely new set of controls. The generic type uses photoplethysmography (PPG) to measure infant pulse rate and oxygen saturation and may include alarms when vital signs exceed preset thresholds.
The category is not exempt from premarket notification. Sponsors seeking to market a substantially equivalent device remain subject to 510(k), with intended use and supporting evidence assessed against the generic type and its controls.
Performance begins with usable sensor data
Clinical performance testing must establish intended performance under anticipated use conditions. It must evaluate confounding variables such as skin pigmentation, demonstrate output consistency and representative data sources and quality for the intended population and environment, and assess all adverse events, including skin irritation. These elements are cumulative, rather than alternative ways to establish performance.
Software verification, validation and hazard analysis must include technical specifications for algorithms, inputs and outputs, together with acceptable incoming sensor data quality controls. Non-clinical testing must demonstrate the ability to detect adequate PPG signal quality and validate any alarms. Accurate measurements under favourable conditions do not, by themselves, establish how a system will manage inadequate input or perform when an alarm is required.
Separate controls address biocompatibility of skin-contacting components and electrical safety and electromagnetic compatibility. A connected interface does not remove the need to support the safety of the physical sensing and electrical components.
Usability must support the caregiver’s response
Human factors and usability testing must show that caregivers can use the device correctly based solely on its labelling and can interpret outputs and understand appropriate next steps. Labelling must identify intended and excluded populations and monitoring conditions, explain measurements and outputs, describe interpretation and appropriate actions, identify situations in which expected performance may not be achieved, and give cleaning instructions and frequency.
The original Dream Sock authorisation provides important product-specific context. Its notifications and displays are intended for infants aged 1 to 18 months and weighing 6 to 30 pounds. It provides notifications only when sufficient data are available and is not intended to notify every unexpected episode. The information supplements caregivers’ decisions to seek medical guidance; it does not replace traditional monitoring, diagnosis or treatment. The product is not intended for infants previously diagnosed with cardiovascular or respiratory disease or conditions.
Those details describe the authorised product and should not automatically be applied as universal indications for all future devices in the category. The codification also does not establish an indication to prevent sudden infant death syndrome. For developers, the useful assessment is whether evidence supports reliable input, validated notifications and an understandable caregiver response within the proposed product’s own intended use.
Sources
- Primary official sourceMedical Devices; Cardiovascular Devices; Classification of the Infant Pulse Rate and Oxygen Saturation Monitor for Over-the-Counter Use (opens in a new tab)U.S. Food and Drug Administration
- Supporting sourceDEN220091 — Dream Sock De Novo classification letter (opens in a new tab)U.S. Food and Drug Administration